tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

FR:ALCLS Stock Latest News

Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
RatingsCautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
21d ago
CLLS
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
PremiumRatings
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
24d ago
CLLS
Cellectis price target lowered to $4 from $5 at Barclays
PremiumThe Fly
Cellectis price target lowered to $4 from $5 at Barclays
25d ago
CLLS
Cellectis SA Reports Q1 2025 Financial Results
PremiumCompany Announcements
Cellectis SA Reports Q1 2025 Financial Results
25d ago
Is CMVLF a Buy, Before Earnings?
PremiumPre-Earnings
Is CMVLF a Buy, Before Earnings?
28d ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
3M ago
ALT
CLLS
Cellectis Reports 2024 Financial Results and Strategic Progress
Premium
Company Announcements
Cellectis Reports 2024 Financial Results and Strategic Progress
3M ago
Cellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating
Premium
Ratings
Cellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating
3M ago
CLLS
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
PremiumCompany Announcements
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
3M ago
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
PremiumCompany Announcements
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
3M ago
Cellectis reports Q4 EPS (64c) vs (17c) last year
PremiumThe Fly
Cellectis reports Q4 EPS (64c) vs (17c) last year
3M ago
AZN
CLLS
Cellectis files to sell 44M ordinary shares for holders
PremiumThe Fly
Cellectis files to sell 44M ordinary shares for holders
5M ago
CLLS
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
5M ago
BLRX
CLLS
Cellectis SA: Financial Growth Amidst Strategic Partnerships
Premium
Company Announcements
Cellectis SA: Financial Growth Amidst Strategic Partnerships
7M ago
Cellectis price target lowered to $5 from $7 at Barclays
Premium
The Fly
Cellectis price target lowered to $5 from $7 at Barclays
7M ago
CLLS
Cellectis reports Q3 EPS (22c), consensus (21c)
PremiumThe Fly
Cellectis reports Q3 EPS (22c), consensus (21c)
7M ago
CLLS
CMVLF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CMVLF Earnings this Week: How Will it Perform?
7M ago
Cellectis publishes pre-clinical evidence MUC1 CAR T-cells reducing certain BC
PremiumThe Fly
Cellectis publishes pre-clinical evidence MUC1 CAR T-cells reducing certain BC
9M ago
CLLS
Cellectis granted orphan drug designation for CLLS52
PremiumThe Fly
Cellectis granted orphan drug designation for CLLS52
10M ago
CLLS
FDA grants Cellectis’ UCART22 ODD and RPDD status for ALL treatment
PremiumThe FlyFDA grants Cellectis’ UCART22 ODD and RPDD status for ALL treatment
11M ago
CLLS
Cellectis treatment of acute lymphoblastic leukemia granted orphan designation
Premium
The Fly
Cellectis treatment of acute lymphoblastic leukemia granted orphan designation
11M ago
CLLS
Cellectis publishes approach for sickle cell disease in Nature Communications
Premium
The Fly
Cellectis publishes approach for sickle cell disease in Nature Communications
12M ago
CLLS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >